生物制药公司CalciMedica依据独立数据监察委员会的评估建议,决定终止其针对急性肾损伤患者的二期临床试验Kourage研究项目。该决定基于对试验中期数据的全面审查,表明继续研究不符合患者权益最大化原则。
生物制药公司CalciMedica依据独立数据监察委员会的评估建议,决定终止其针对急性肾损伤患者的二期临床试验Kourage研究项目。该决定基于对试验中期数据的全面审查,表明继续研究不符合患者权益最大化原则。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.